|
 |
| Features |
|
|
 |
PET/CT: Market & Business Models for Ownership |
| |
by George Wiley |
| |
PET/CT is the last major modality to be widely deployed, and indications for it are
broadening; yet, just as the future looks brightest, here comes the DRA. |
|
|
|
CT Colonography: Current Status and Economics |
| |
by Matthew A. Barish, MD; Michael E. Zalis, MD; and Gordon J. Harris, PhD |
| |
Although CT colonography continues to be stymied by erratic reimbursement policies,
codes and indications do exist, and some private payors are reimbursing for all screening
patients. |
|
|
|
|
|
|
|
|
|
| Sections |
|
|
|
|
| Departments |
|
|
|
|
|
|
|
|
|
|
Special Section
The Kidney & Contrast Media: A Practical Guide to Predicting and Preventing Contrast-induced Nephropathy |
|
|
|
Strategies to Reduce the Risk of Contrast-induced Nephropathy |
| |
by Richard Solomon, MD |
| |
Because patients who develop contrast-induced nephropathy have higher morbidity, mortality, and use of hospital resources than those who do not, a proactive approach to reducing risk is imperative. |
|
|
|
New Developments in Prophylaxis Against Contrast-induced Nephropathy |
| |
by Jason Fought, MD |
| |
Many new approaches to preventing CIN that warrant further evaluation, including induced hypothermia, targeted renal therapy, hemofiltration, and contrast capture. |
|
|
|
Estimating Glomerular Filtration Rates to Assess Renal Function |
| |
by Alan Segal, MD |
| |
Emerging methods for calculating and interpreting the eGFR will help radiologists assess renal function and the potential risk of CIN. |
|
|
|
Predicting and Preventing Contrast-Induced Nephropathy |
| |
by George M. Ebert, MD, PhD |
| |
The incidence rate of contrast-induced nephropathy may surprise many radiologists. |
|
| Sponsored by Tyco Healthcare/Mallinckrodt |
|
Resources
